4Saravanan S,Pari L.Protective effect of thymol on high fat diet induced diabetic nephropathy in C57BL/6J mice[J].Chem Biol Interact,2016,245(5):1-11. 被引量：1
5Tao Li,Hai-feng Xi,Hong-min Luo,et al.Association of the NAD(P)H oxidase p22 phox gene C242T polymorphism with type 2 diabetes mellitus,diabetic nephropathy,and carotid atherosclerosis with type 2 diabetes mellitus:A meta-analysis[J].Meta Gene,2015,6(36):1-8. 被引量：1
10Chung-Ze Wu,Li-Chien Chang,Yuh-Feng Lin,et al.Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy Original Research Article[J].Clinical Biochemistry,2015,48(18):1324-1329. 被引量：1
7Abe M, Okada K, Maruyama T, et al. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive pa- tients with stage 3-5 chronic kidney disease[J]. Hypertens Res, 2009,32(4) :270. 被引量：1
8Coyle D, Rodby R, Soroka S, et al. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective[J]. Clin Ther, 2007,29 (7) : 1 508. 被引量：1
9Coronel F, Cigarran S, Garcia-Mena M, et al. Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI[J]. Nefrologia, 2008, 28(1):56. 被引量：1
10Palmer A J, Valentine W J, Ray JA. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis[J], Int J Clin Pract, 2007,61(10) : 1 626. 被引量：1
